Always patient and willing to help.
Brings real-world insights to the classroom.
This comment is not public.
Dr. Rene Jaeggi holds a Doctor of Philosophy from James Cook University and is affiliated with the Discipline of Medicine within the College of Medicine and Dentistry at James Cook University, Townsville, Australia. He is a key researcher at the Queensland Research Centre for Peripheral Vascular Disease, where he has contributed significantly to clinical trials investigating interventions for abdominal aortic aneurysm (AAA) pathology. His expertise encompasses vascular imaging, angiography, peripheral vascular diseases, atherosclerotic vascular diseases, and arteries. Jaeggi serves in roles such as Clinical Trials Manager and Global Project Manager for vascular research projects, including those sponsored by James Cook University and involving collaborations across Australia.
Jaeggi's publication record includes 18 works cited over 560 times, spanning pharmacology and vascular research. Key contributions feature outcomes from the FAME trial, 'A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology' (2020); the FAME-2 trial, 'Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm' (2018); the IMAGEN study protocol, 'Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN)' (2017); and the TEDY trial protocol, 'TElmisartan in the management of abDominal aortic aneurYsm (TEDY)' (2015). Earlier publications address hepatic effects of herbal extracts, including 'Hepatic effects of Cimicifuga racemosa extract in vivo and in vitro' (2007), 'Hepatocellular toxicity of kava leaf and root extracts' (2008), and studies on willow bark extract polyphenols (2006-2007). His work supports multi-centre randomized controlled trials funded by the Australian National Health and Medical Research Council, Queensland Government, and James Cook University, advancing understanding of AAA progression and potential pharmacological managements.
